• Cryptomonnaies
  • Marchés de Prédiction
  • Actualités
  • Trading Agentique
  • Articles
  • Ligues

Rechercher des Cryptomonnaies

Cryptomonnaies en tendance

CoinRithm

Entreprise

Entité légale
Bees-x Limited
Numéro de société
13308136
Constituée en
England and Wales
Siège social
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm est un service d'information et de recherche exploité par Bees-x Limited. Il n'est pas autorisé par la Financial Conduct Authority (FCA) à exercer des activités réglementées, et rien sur ce site ne constitue un conseil financier.

Explorer

CryptomonnaiesMarchés de PrédictionActualitésArticlesAgent ArenaLigues

Fonctionnalités

Tableau de bordÉchange FictifTrading AgentiquePortefeuilleListe de suiviParamètres

Entreprise

À Propos de NousMethodologiePour les coursConditions d'utilisationPolitique de ConfidentialitéPolitique en Matière de CookiesAvertissement

Support

Contactez le SupportFAQKit développeurDocs MCP

Réseaux

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Tous droits réservés.
Disponible sur Google PlayTélécharger sur l'App Store
  • Accueil
  • MarchésMarchés de Prédiction
  • Actualités
  • Tableau de bord
  1. Marchés de Prédiction
  2. Régulation
  3. FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

RégulationOne-OffHealth & Medicine6mo
KalshiKalshiVérifier la disponibilitéKYC requis2% de frais
Probabilité implicite actuelle
Oui
Oui 0%
Qualite du marche

24 / 100

Faible qualité
Volume 24h

0 €

Liquidité

0 €

Faible liquidité
Achat / Vente

67.0% / 74.0%

Spread

10.4%

Spread large
Données du marché

Mis à jour il y a 4 minutes

17 juin 26, 21:301 janv. 27, 4:59

Tendances

Résultat24hProbabilité
Oui
Oui
0%
Non
Non
100%

Résultat choisi

Yes0%

Règles

If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars.
  • Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial.
  • In the EPICS-III trial , it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.

Marchés Associés

Manifold Markets

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

994,7 €
Oui: 22.2%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Will China have more phase 3 drug trials than the United States in year X?

367,9 €
2026: 33%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Will estradiol be available over-the-counter in the US before 2030?

303 €
Oui: 8.2%Manifold MarketsMANIFOLD MARKETS
FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)

FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)

0 €
Oui: 0%KalshiKALSHI
Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

38,2 k €
Oui: 4%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

5,2 k €
Oui: 11%PolymarketPOLYMARKET

Actifs dans ces sujets

BitcoinBTC$64,629.89-1.78%EthereumETH$1,757.30-2.12%SolanaSOL$72.45-1.60%DogecoinDOGE$0.0864-1.25%XRPXRP$1.19-2.24%BNBBNB$603.36-0.41%

Actualités Associées

Binance MiCA License Application Cleared by Greek Regulator, June 30 Update AwaitedBlockchain ReporterCLARITY Act faces ethics showdown as David Nage eyes July voteCrypto NewsBinance EU Access at Risk as Greek Regulator Set to Reject MiCA License BidBlockchain ReporterSolana Institute warns Senate against weakening CLARITY ActCrypto NewsSummer of crypto (regs): State of Crypto CoindeskPhilippine Central Bank Bars VASPs From Listing Privacy CoinsBlockchain Reporter

Règles

If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars.
  • Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial.
  • In the EPICS-III trial , it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.